

**To:** (10)(2e) (10)(2e) @minvws.nl; (10)(2e) (10)(2e) @minvws.nl  
**Cc:** Berg, A. (Angelique) (10)(2e) @minvws.nl; (10)(2e) (10)(2e) @minvws.nl; (10)(2e)  
(FIN/PPI) (10)(2e) @minfin.nl  
**From:** (10)(2e)  
**Sent:** Fri 6/12/2020 2:36:12 PM  
**Subject:** FW: AZ Persbericht  
[EUROPE VACCINE RNS 1350BST.docx](#)  
[ATT00001.txt](#)

Ik krijg net deze mail, op zich fijn dat ze willen afstemmen lijkt me.  
(10)(2e) kun jij even tegenlezen?

(10)(2a)

-----Oorspronkelijk bericht-----

**Van:** (10)(2e) <(10)(2e) @astrazeneca.com>  
**Verzonden:** vrijdag 12 juni 2020 16:31  
**Aan:** (10)(2e) <(10)(2e) @minvws.nl>  
**Onderwerp:** AZ Persbericht

Hierbij het draft persbericht van AstraZeneca voor informatie.

---

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at [www.astrazeneca.com](https://www.astrazeneca.com)<<https://www.astrazeneca.com>>